|
|||||
|
|
The selective metabotropic glutamate receptor 5 antagonist mavoglurant (AFQ056) reduces the incidence of reflux episodes in dogs and patients with moderate to severe gastroesophageal reflux disease |
|
| Authors: | M.‐L. Rouzade‐Dominguez N. Pezous O. J. David R. Tutuian S. Bruley des Varannes J. Tack P. Malfertheiner H.‐D. Allescher M. Ufer A. Rühl |
| Affiliation: | 1. Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland;2. Universit?tsspital Zürich, Zürich, Switzerland;3. CHU‐H?tel Dieu Nantes, Nantes, France;4. University Hospitals Leuven, Leuven, Belgium;5. Universit?tsklinikum Magdeburg, Magdeburg, Germany;6. Klinikum Garmisch‐Partenkirchen, Garmisch‐Partenkirchen, Germany |
| Abstract: | |
| Keywords: | gastroesophageal reflux disease (GERD) mavoglurant metabotropic glutamate receptor transient esophageal sphincter relaxations (TLESRs) |